News

The clinical trial is designed to assess the safety and tolerability of darinaparsin injection for the treatment of peripheral T-cell lymphoma (PTCL). Darinaparsin is a mitochondrial-targeted agent being

Movianto will continue to exclusively store and distribute childhood vaccines. The Department of Health undertook a tendering exercise to test the market for service and value for money,

The companies have commenced the work at CMC Biologics’ Bothell manufacturing facility. Daiichi Sankyo Biopharmaceutical Technology Research Laboratories vice president Junichi Koga said CMC Biologics is known for

According to the company, the new grades do not require blending and offer predictable and reproducible drug release profiles even under conditions such as in a full stomach,

The drug candidate, which was identified using the Ligand Activated Therapy (LAT) approach, is the second product in the company’s pain therapy range. KP511 demonstrated superior pharmacological characteristics

The open label, multicenter phase I/II study comprising 20 patients evaluated the tolerability and efficacy of OvaSave, an antigen-specific regulatory T cell-based immunotherapy. The data demonstrated that OvaSave

DAC HYP, a humanized monoclonal antibody, is subcutaneous formulation of daclizumab which binds to CD25, a receptor subunit that is expressed at high levels on T cells that

The system, which features latest information management technology, is said to help pharma professionals access and use data across the entire drug research and development life cycle, Reuters

Previously, Liu served at Irvine – based eGene as founder and CEO and set the company for acquisition by Qiagen in 2007. He has experience in bio-products development,